Provided are a novel compound capable of improving the luminous efficiency, stability and lifespan of an element, an organic electronic element using the same, and an electronic device thereof.

A compound and method for detecting hypoxic cells and tissue are provided. The compound includes a probe selected from the group consisting of a hypoxia sensitive 2-nitroimidazole containing fluorescence imaging probe, a hypoxia sensitive reversible ON-OFF fluorescence imaging probe, a hypoxia sensitive azo-based fluorescence imaging probe, and combinations thereof. The method includes contacting the cells or tissue with the probe of any one of claims 1-13 and detecting fluorescent intensity of the cell or tissue, wherein increased fluorescent intensity indicates that the cells or tissue is hypoxic. Also provided are a method of synthesizing the compound and a method for synthesizing a therapeutic agent including the compound.

The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel aminated homoharringtonine derivatives of formula (I) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. ##STR00001##

The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel aminated homoharringtonine derivatives of formula (I) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. ##STR00001##

Described are a compound of formula (II) or (III):

##STR00001##

The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

Described are a compound of formula (II) or (III): ##STR00001## The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

Described are a compound of formula (II) or (III): ##STR00001## The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.